Hester Biosciences Limited (BSE:524669) will look for acquisitions. Rajiv Gandhi, Chief Executive Officer and Managing Director said, ?We are looking at tying up, acquiring some distribution companies in a few countries. So all these sort of things, we are just looking at options, which I have mentioned to you for the last 2, 3 years, either some distribution companies, manufacturing. Unfortunately, we have not been able to lay our hands on it. But this is what we are looking. And the African model would be, at this point, let's take it that it would be a dynamic fluid model. As we move, we will structure -- sorry, structure ourselves?.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
HESTER BIOSCIENCES LIMITED 
